

Expanding horizons for patients with Pompe disease: Using data to guide clinical practice



Prof. Tahseen Mozaffar
UCI School of Medicine
Irvine, CA, USA



Dr Jennifer L Cohen
Duke University
Durham, NC, USA



Prof. Benedikt Schoser
Ludwig Maximilians University
Munich, Germany

Recorded following 29th Annual Congress of the World Muscle Society, Prague, Czechia, 8–12 October 2024,
and 21st Annual WORLDSymposium, San Diego, CA, USA, 3–7 February 2025

Disclaimer

- *Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions*
- *The presenting faculty have been advised by USF Health and touchIME to ensure that they disclose any such references made to unlabelled or unapproved use*
- *No endorsement by USF Health and touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in USF Health and touchIME activities*
- *USF Health and touchIME accept no responsibility for errors or omissions*

Treating Pompe disease for the long-term and in the real world

Prof. Tahseen Mozaffar
UCI School of Medicine
Irvine, CA, USA



Recorded following 29th Annual Congress of the World Muscle Society, Prague, Czechia, 8–12 October 2024,
and 21st Annual *WORLDSymposium*, San Diego, CA, USA, 3–7 February 2025

119: Retrospective cohort study evaluating the disease burden of patients with Pompe disease treated with ERT in the United States

Pillai NR, et al.



Patient cohort N=105 IOPD: n=50 LOPD: n=55

Comorbidities of interest

	Respiratory	Ambulatory	GI	CV
IOPD	84.5%	57.4%	67.8%	16.9%
LOPD	79.4%	54.3%	33.4%	28.7%

Cumulative incidence of most comorbidities, particularly respiratory infections, increased over time

Patterns of ERT use

	IOPD	LOPD
Discontinued 1st ERT after 12 months	35.3%	33.0%
Discontinued 1st ERT after 24 months	48.7%	54.5%
Had a change in ERT dose	42.4%	20.6%
ERT dose decrease	36.4%	14.7%
ERT dose increase	14.7%	17.6%

Utilization of support/therapy services

	ITI/IVIg	Ambulatory	Respiratory	Occupational	Speech	Nutritional	Physical
IOPD	48.6%	8.3%	15.1%	27.8%	59.5%	47.3%	66.9%
LOPD	1.8%	11.1%	17.0%	3.7%	3.9%	11.2%	31.8%

The use of occupational, speech and physical therapy increased over time for both groups

Pompe disease causes a substantial disease burden for patients despite standard-of-care ERT, suggesting alternative treatments are needed

331: Retrospective cohort study evaluating the economic burden of patients with Pompe disease treated with ERT in the United States

Steiner RD, et al.



Patient cohort N=105 IOPD: n=50 LOPD: n=55

Healthcare resource utilization, %

	IOPD	LOPD
Used ≥1 outpatient services	94.0	89.1
Require ≥1 all-cause hospitalization	46	29
Require ≥1 Pompe-related hospitalization	44	24

Mean, n

All-cause outpatient visits PMPM	8.7	3.9
Pompe-related outpatient visits PMPM	5.2	1.7

Healthcare costs:

	IOPD	LOPD
All-cause (total)	\$950,380	\$1,857,823
All-cause (PMPM)	\$31,658	\$56,615
ERT pharmacy (total)	\$211,536	\$566,938
ERT pharmacy (PMPM)	\$7,046	\$17,277
Pompe-related* (total)	\$804,918	\$1,329,693
Pompe-related* (PMPM)	\$25,999	\$39,344

The majority of costs were outpatient- or ERT-related

Pompe disease causes a substantial economic burden for patients treated with ERT, primarily due to outpatient visits and ERT prescription costs, highlighting the need for new, less expensive treatments

*Pompe-related healthcare costs included outpatient, hospitalization and prescription costs.

ERT, enzyme replacement therapy; IOPD, infantile-onset Pompe disease; LOPD, late-onset Pompe disease; PMPM, per member per month.

Steiner RD, et al. Presented at 21st Annual WORLDSymposium 2025. San Diego, CA, USA. 3–7 February 2025. Abstr. 331.

248: Pompe disease in Sweden: A real-world evidence study investigating disease burden, treatment patterns for ERT and concomitant medications

Nordin S, et al.

Insights on treatment patterns in a Swedish cohort


	LOPD (n=14)	IOPD (n=5)
Disease prevalence at CSTP, per 1 million	1.3	0.5
Mean age at diagnosis, years (SD)	43.2 (22.3)	0.5 (0.5)
Mean time from symptom onset to diagnosis, years (SD)	9.5 (13.5)	*
Median time from symptom onset to diagnosis, years (IQR)	5.4 (2.3–8.2)	*
Median time from diagnosis to ERT initiation, years (95% CI)	1.5 (0.5–16.6)	*



Biweekly
ERT dose

LOPD (n=9): **20 mg/kg** (standard dose)
IOPD (n=5): **24.0 mg/kg** (SD ±8.9)
(maximum 40.0 mg/kg)

In patients with LOPD (n=14):



receiving concomitant
respiratory-management medication

6 patients required ventilation/other respiratory management
age at first requirement

62.8 years



Diagnoses
prior to
LOPD

71% Symptoms, signs and abnormal clinical/
laboratory findings not elsewhere classified

53% Endocrine, nutritional and metabolic diseases

53% Nervous system diseases

41% Respiratory system diseases

*Not reported in published abstract. CI, confidence interval; CSTP, cross-sectional timepoint; ERT, enzyme replacement therapy; IOPD, infantile-onset Pompe disease; IQR, interquartile range; LOPD, late-onset Pompe disease; SD, standard deviation. Nordin S, et al. Presented at 21st Annual *WORLD Symposium* 2025. San Diego, CA, USA. 3–7 February 2025. Abstr. 248.

225: POM-005: A global, prospective, observational registry of people living with Pompe disease

McIntosh P, et al.



POM-005 (NCT06121011): A global, prospective, observational registry to assess clinical outcomes in people living with Pompe disease, regardless of current/previous therapy status

Inclusion criteria



People with IOPD or LOPD based on documented GAA enzyme deficiency and/or GAA genotyping, regardless of time since diagnosis



Data from a long-term cohort of patients from CIPA + MIG in clinical trials/early access programmes continuing therapy post-approval



Ineligible: Patients currently receiving investigational therapy for Pompe in a clinical trial, compassionate use or expanded-use programme



- ~100 study sites globally
- 500 participants anticipated
 - 1st participant enrolled: February 2024
- Study completion: ~December 2034
- ≥5 years prospective follow-up
- Data at enrolment will include historical data (≤5 years prior)



Objectives

- Long-term real-world effectiveness (e.g. biomarkers, motor and pulmonary function)
- Long-term safety (e.g. IARs, pregnancy exposure)
- HR-QoL and PROs
- Characterize disease natural history

Treatment switching for patients with Pompe disease

Prof. Tahseen Mozaffar
UCI School of Medicine
Irvine, CA, USA



Prof. Benedikt Schoser
Ludwig Maximilians
University
Munich, Germany



Recorded following 29th Annual Congress of the World Muscle Society, Prague, Czechia, 8–12 October 2024,
and 21st Annual *WORLDSymposium*, San Diego, CA, USA, 3–7 February 2025

P668: Pompe Registry: Real-world experience of patients with LOPD who switched therapy from alglucosidase alfa (ALG) to avalglucosidase alfa (AVA)

Schoser B, et al.




Baseline characteristics (Data download: 5 April 2024)

Baseline characteristics (Data download: 5 April 2024)	Patients
Pompe Registry patients with LOPD who had switched treatments, N	210
Time on ALG pre-switch	
<5 years, n (%)	85 (40.5%)
≥5 years, n (%)	125 (59.5%)
Females, n (%)	110 (52.4%)
Age at Pompe disease diagnosis, n	209
Mean, years (SD)	35.2 (21.41)
Mean patients on ALG <5 years pre-switch, years (SD)	33.7 (22.39)
Mean patients on ALG ≥5 years pre-switch, years (SD)	34.5 (20.74)
Median, years (min, max)	35.6 (0, 77.5)
Median patients on ALG <5 years pre-switch, years (min, max)	34.7 (0, 70.6)
Median patients on ALG ≥5 years pre-switch, years (min, max)	36.4 (0, 77.5)



Distribution of patients with LOPD by region of residence




Most (59.5%; 125/210) patients with LOPD in the Pompe Registry, who had switched treatment from ALG to AVA, had received ALG for ≥5 years pre-switch

P668: Pompe Registry: Real-world experience of patients with LOPD who switched therapy from alglucosidase alfa (ALG) to avalglucosidase alfa (AVA)

Schoser B, et al.

Pulmonary function



Preliminary results showed that effectiveness measures of **respiratory outcomes** were **relatively stable**


P668: Pompe Registry: Real-world experience of patients with LOPD who switched therapy from alglucosidase alfa (ALG) to avalglucosidase alfa (AVA)

Schoser B, et al.


Motor function

● Overall ● ALG <5 y pre-switch ● ALG ≥5 y pre-switch

● Last assessment pre-switch ● Last assessment post-switch <1 y



Mean 6MWT distance at last assessment pre-switch from ALG to AVA for patients with LOPD, m



6MWT distance at last assessment pre-switch and last assessment within 1 y post-switch, * m

Preliminary results showed that effectiveness measures of **motor outcomes** were **relatively stable**

*Bottom and top of box indicate 25th and 75th percentiles; line within the box indicates median; whiskers indicate 5th and 95th percentiles.

6MWT, 6-minute walk test; ALG, alglucosidase alfa; AVA, avalglucosidase alfa; LOPD, late-onset Pompe disease.





Schoser B, et al. Presented at: 29th Annual Congress of the World Muscle Society 2024, Prague, Czechia. 8–12 October 2024. P668.

P668: Pompe Registry: Real-world experience of patients with LOPD who switched therapy from alglucosidase alfa (ALG) to avalglucosidase alfa (AVA)

Schoser B, et al.

Biomarkers

● Overall ● ALG <5 y pre-switch ● ALG ≥5 y pre-switch ● Last assessment pre-switch ● Last assessment post-switch <1 y



Preliminary results showed that **biomarkers associated with disease burden decreased (improved) after treatment switch**

*Bottom and top of box indicate 25th and 75th percentiles; line within the box indicates median; whiskers indicate 5th and 95th percentiles.

ALG, alglucosidase alfa; AVA, avalglucosidase alfa; CK, creatine kinase; Glc4/Hex4, glucose tetrasaccharide/hexose tetrasaccharide; LOPD, late-onset Pompe disease.

Schoser B, et al. Presented at: 29th Annual Congress of the World Muscle Society 2024, Prague, Czechia. 8–12 October 2024. P668.

303: Clinically important improvements in 6MWD and FVC in adults with LOPD switching from alglucosidase alfa (ALG) to cipaglucosidase alfa plus miglustat (CIPA + MIG) in the PROPEL study
Schoser B, et al.

 Baseline characteristics	CIPA + MIG (n=65)	ALG + PBO (n=30)
Median age, years (range)*	48.0 (21–74)	46.5 (24–66)
Median age at diagnosis, years (range)*	39.0 (1–63)	39.0 (7–62)
Males, n (%)	28 (43.1)	14 (46.7)
Median ERT duration, years (IQR)*	7.6 (4.3–10.2)	7.1 (3.8–10.4)
ERT duration, n (%)		
≥2 to <3 years	4 (6.2)	5 (16.7)
≥3 to <5 years	16 (24.6)	6 (20.0)
≥5 years	45 (69.2)	64 (67.4)
Mean 6MWD, meters (SD) [†]	346.9 (110.2)	334.6 (114.0)
Mean predicted sitting FVC, % (SD) [†]	67.9 (19.1)	67.5 (21.0)

*Data from Kishnani PS, et al. *J Patient Rep Outcomes*. 2024;8:132. [†]Data from Schoser B, et al. *Lancet Neurol*. 2021;20:1027–37.


6MWD, 6-minute walk distance; ALG, alglucosidase alfa; CIPA, cipaglucosidase alfa; ERT, enzyme replacement therapy; FVC, forced vital capacity;

IQR, interquartile range; LOPD, late-onset Pompe disease; MIG, miglustat; PBO, placebo; SD, standard deviation.


Schoser B, et al. Presented at: *WORLD Symposium 2025*, San Diego, CA, USA. 3–7 February 2025. Abstr. 303.

303: Clinically important improvements in 6MWD and FVC in adults with LOPD switching from alglucosidase alfa (ALG) to cipaglucosidase alfa plus miglustat (CIPA + MIG) in the PROPEL study Schoser B, et al.

**Response level by baseline 6MWD:
Based on 6MWD CFBL to week 52 and MCID* (%)**



**Response level by baseline 6MWD:
Based on predicted FVC CFBL to week 52 and MCID[†] (%)**



*Response levels (number of responders) determined: improving, 6MWD CFBL to week 52 ≥MCID; stable, -MCID <6MWD CFBL to week 52 <MCID; worsening, 6MWD CFBL to week 52 ≤-MCID.

[†]Response levels (number of responders) determined: improving, FVC CFBL to week 52 ≥3%; stable, -3% <FVC CFBL to week 52 <3%; worsening, FVC CFBL to week 52 ≤-3%.


6MWD, 6-minute walk distance; ALG, alglucosidase alfa; CFBL, change from baseline; CIPA, cipaglucosidase alfa; FVC, forced vital capacity; LOPD, late-onset Pompe disease;

MCID, minimal clinically important difference; MIG, miglustat; PBO, placebo.

Schoser B, et al. Presented at: WORLDSymposium 2025, San Diego, CA, USA. 3–7 February 2025. Abstr. 303.

303: Clinically important improvements in 6MWD and FVC in adults with LOPD switching from alglucosidase alfa (ALG) to cipaglucoisidase alfa plus miglustat (CIPA + MIG) in the PROPEL study
Schoser B, et al.


Overall proportion of patients with clinically relevant improvement or worsening in 6MWD and/or FVC after switching ERT in PROPEL



Around **half** as many patients treated with CIPA + MIG **worsened** compared with ALG

CIPA + MIG


ALG + PBO



Nearly **4×** as many patients who switched to CIPA + MIG **improved** in 6MWD and/or FVC vs those remaining on ALG

More patients achieved clinically relevant improvement in 6MWD and/or FVC and fewer worsened with CIPA + MIG vs ALG

303: Clinically important improvements in 6MWD and FVC in adults with LOPD switching from alglucosidase alfa (ALG) to cipaglucosidase alfa plus miglustat (CIPA + MIG) in the PROPEL study
Schoser B, et al.



Safety profiles of CIPA + MIG and ALG + PBO in the ERT-experienced PROPEL study population were similar

*Relatedness to treatment determined by the investigator. [†]Anaphylactic reaction and chills. [‡]Cerebrovascular accident (stroke) unrelated to study drug.
 6MWD, 6-minute walk distance; ALG, alglucosidase alfa; CIPA, cipaglucosidase alfa; ERT, enzyme replacement therapy; FVC, forced vital capacity; LOPD, late-onset Pompe disease;
 MIG, miglustat; PBO, placebo; TEAE, treatment-emergent adverse event. Schoser B, et al. Presented at: *WORLD Symposium 2025*, San Diego, CA, USA. 3–7 February 2025. Abstr. 303.

- **46: CIPA plus MIG in LOPD:**
Two non-ambulatory patients switching from high-dose, high-frequency ALG
Byrne BJ, et al.

CIPA + MIG showed long-term benefits with few AEs




N=2

- Aged 18–25 years during study
- Diagnosed before age 2 years
- Patient 1: female; Patient 2: male
- Same genotype (C.1210G>A;C.1924G>T)

- Receiving ALG since age 4–6 years
- Weekly high-dose (40 mg/kg)

Upper body QMT Score, kg



Following switch to CIPA + MIG:

- Patients reported improvement in overall physical well-being
- Physicians mainly rated health status as improved
- uHex4 and sCK ↓ vs baseline at every assessment

CIPA + MIG: well-tolerated with 11 TEAEs in total by data cut-off*

- No serious TEAEs reported
- No infusion-related reactions
- None were deemed treatment-related, apart from fatigue in Patient 2

70: Outcomes of a pediatric patient with LOPD switching from high-dose, high-frequency ALG to standard-dose CIPA + MIG

DeArmey S, et al.

Improvement or stability seen over 160 weeks' treatment




N=1

- Male, aged 1 year at diagnosis (in 2006)
- On ALG for 14 years before switching to standard-dose CIPA + MIG on entering study ATB200-04

- Aged 15 at baseline
- Transitioned to approved CIPA + MIG at age 18 years

Improvements in motor function (baseline to week 156):



CIPA + MIG: Similar safety outcomes to those seen in adults

- All AEs were non-serious, and mild or moderate in severity

*Data cut off: 13 December 2021. 6MWD, 6-minute walk distance; AE, adverse event; ALG, alglucosidase alfa; CIPA, cipagluscosidase alfa; FVC, forced vital capacity; LOPD, late-onset Pompe disease; MIG, miglustat; PGIC, Physician Global Impression of Change; pred., predicted; QMT, quantitative muscle test; sCK, serum creatine kinase; SGIC, Subject Global Impression of Change; TEAE, treatment-emergent AE; uHex4, urine hexose tetrasaccharide.
1. Byrne BJ, et al. Presented at: World Muscle Society Congress 2024, Prague, Czech Republic. 8–12 October 2024. Abstr. 657P, and WORLDSymposium 2025, San Diego, CA. USA. 3–7 February 2025. Abstr. 46; 2. DeArmey S, et al. Presented at: WORLDSymposium 2025, San Diego, CA. USA. 3–7 February 2025. Abstr. 70.

Applying data to clinical practice for patients with Pompe disease

Prof. Tahseen Mozaffar
UCI School of Medicine
Irvine, CA, USA



Recorded following 29th Annual Congress of the World Muscle Society, Prague, Czechia, 8–12 October 2024,
and 21st Annual *WORLDSymposium*, San Diego, CA, USA, 3–7 February 2025

139: Miglustat: a first-in-class enzyme stabilizer for LOPD

Hopkin RJ, et al.

Impact of MIG on functional outcomes of CIPA

- MIG stabilizes CIPA at pH 7.4 (blood)
- MIG increased exposure to CIPA in Gaa $-/-$ mice and resulted in an improvement in glycogen clearance and grip strength
- MIG increases CIPA exposure in humans by a greater extent than mice

Change in AUC of total GAA-protein concentration with CIPA + MIG in mice and humans



↑ 6.8%



↑ 28.5%

Safety profile of CIPA + MIG from pooled analysis of 3 trials (N=151)

Any TEAE	98.7%
TEAE related to MIG only	13.9%
Serious TEAE related to MIG only	0

In a head-to-head study (PROPEL);
CIPA + MIG has a similar safety profile to ALG

CIPA + MIG is associated with a
reduction in Hex4 and CK levels vs CIPA alone

The combination of CIPA + MIG improves delivery of rhGAA, reduces biomarker levels, and is well tolerated in adults with LOPD

236: AT845 gene replacement therapy for LOPD: An update on safety and preliminary efficacy data from FORTIS, a phase I/II open-label clinical study

Mozaffar T, et al.



Patient cohort N=6

Safety

All liver events

(ALT/AST increases observed in 5 of the 6 participants and deemed possibly related to AT845)

have been **asymptomatic**
and have

responded to immunosuppressive treatment with glucocorticoid therapy

Efficacy

- A clear transduction of AT845 was seen
- Patients demonstrated marked improvement in muscle GAA levels and activity

Discontinued ERT*

n=5

Remain off ERT

n=5

- FVC
- 6MWT
- PROMIS-fatigue
- R-PAct

Assessments stable for first 4 participants for ≤ 2 -years post-dosing, including following ERT withdrawal

Patients receiving AT845 remained clinically stable while off ERT for at least 1 year and up to 3.5 years

*At 10, 15, 15, 17 and 24 weeks, respectively.

6MWT, 6-minute walk test; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ERT, enzyme replacement therapy; FVC, forced vital capacity; GAA, acid alpha-glucosidase; LOPD, late-onset Pompe diseases; PROMIS, Patient Reported Outcomes Measurement Information System; R-PAct, Rasch-built Pompe-specific activity. Mozaffar T, et al. Presented at 21st Annual WORLDSymposium 2025. San Diego, CA, USA. 3–7 February 2025. Abstr. 236.